08/12/2025
3-year-old Isabel Danhakl has a rare form of eye cancer called retinoblastoma. It typically affects children younger than 5 and, even after successfully undergoing chemotherapy, patients never officially go into remission and are monitored well into adulthood.
Unlike most cancers, retinoblastoma can’t be biopsied since taking a sample could cause the cancer cells to spread. But there was hope—a new test pioneered by CHLA's Dr. Jesse Berry called liquid biopsy where, using a tiny drop of fluid from the eye, clinicians can know definitively whether a child has retinoblastoma. There was just one problem: Until the liquid biopsy was validated in a certified lab, it could not be used clinically.
That’s when Isabel’s parents, Victoria and Thomas, stepped in to help. With a generous gift from the Danhakl Family Foundation, of which they are both trustees, Dr. Berry’s lab was able to collaborate with CHLA’s Center for Personalized Medicine in late 2022. This led to the creation of a validated clinical test and new platform called LBSeq4Kids, which sequences DNA using a pea-size amount of aqueous humor and guides treatment for children with retinoblastoma.
Read more: https://www.chla.org/blog/hospital-news/familys-vision-future